This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

Practical considerationsMonitoring patients on Cibinqo1
Scroll left to view table
Laboratory measure Monitoring guidance Action
Platelets​​​​​​​​​​​​​​ • Before treatment initiation
• 4 weeks after initiation
• Thereafter according to clinical guidelines
• Discontinue treatment if platelets are <50 x 103/mm3
Lymphocytes • Treatment should be interrupted if ALC is <0.5 x 103/mm3 and may be restarted once ALC returns above this value. Treatment should be discontinued if confirmed
​​​​​​​
​​​​​​​• Treatment should be interrupted if ANC is <1 x 103/mm3 and may be restarted once ANC returns above this value
Neutrophils
Haemoglobin • Treatment should be interrupted if haemoglobin <8 g/dL and may be restarted once haemoglobin returns above this value
Lipids  
• Before treatment initiation
• 4 weeks after initiation
​​​​​​​• Thereafter according to clinical guidelines


• Patients should be monitored according to clinical guidelines for hyperlipidaemia

Serious infections
If a patient develops a serious infection, sepsis, or opportunistic infection, consider interruption of Cibinqo until the infection is controlled. Treatment must not be initiated in patients with an active, serious systemic infection.

Vaccines
No data are available on the response to vaccination in patients receiving Cibinqo. Use of live, attenuated vaccines during or immediately prior to Cibinqo therapy is not recommended. It is recommended that patients be brought up to date with all immunisation, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines.

Tuberculosis
Patients should be screened for TB before starting treatment and consider yearly screening for patients in highly endemic areas for TB. Cibinqo must not be given to patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, preventive therapy for latent TB should be started prior to initiation of Cibinqo.

Viral reactivation
If a patient develops herpes zoster, temporary interruption of treatment should be considered until the episode resolves. Discontinuation or interruption of Cibinqo until the resolution of an eczema herpeticum infection should be considered, depending on the seriousness of the event. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy and during therapy with Cibinqo.​​​​​​​

Elderly
​​​​​​​Patients 65 years and older were more likely to develop low platelet and ALC values in clinical trials. A higher proportion of patients aged 65 years and older discontinued from clinical studies and were more likely to have serious adverse events compared with younger patients; the incidence rate of herpes zoster in this age group was higher than for younger patients. There are limited data in patients above 75 years of age.

PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION​​​​​​​.

Explore moreDosing

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosingLoading
Patient resources

Access resources to help you support your patients on Cibinqo.

View resourcesLoading

ALC=absolute lymphocyte count; ANC=absolute neutrophil count; TB=tuberculosis.

Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.
PP-CIB-GBR-0069. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​